The growth and metastasis of the majority of tumours depends on the formation of new blood vessels. Angiogenic factors that are released by tumour cells promote activation, proliferation and migration of endothelial cells to the tumour tissue, allowing for rapid formation of functional neo-vessels.
Endothelial cells contribute to tumour angiogenesis, and can originate from sprouting or co-option of neighbouring pre-existing vessels. Emerging evidence indicates that bone-marrow-derived circulating endothelial progenitor cells (CEPs) can contribute to the angiogenesis and growth of certain tumours.
The introduction of wild-type bone marrow CEPs, which express the VEGF receptor (VEGFR)-2, restores tumour angiogenesis and growth in tumour-resistant mice, indicating that bone-marrow-derived cells are essential for the angiogenesis and growth of certain tumours. Co-mobilization of VEGFR1+ haematopoietic stem and progenitor cells facilitate the incorporation of CEPs into functional tumour neo-vessels.
Mobilization of CEPs and pro-angiogenic haematopoietic cells from bone marrow is a dynamic process that requires angiogenic-factor-mediated activation of metalloproteinases (MMPs), specifically MMP-9, which lead to the release of soluble KIT ligand (sKitL). sKitL promotes the proliferation and motility of CEPs and haematopoietic cells within the bone-marrow microenvironment, thereby laying the framework for their mobilization to the peripheral circulation.
Inhibition of either VEGFR1 or VEGFR2 signalling can only partially block tumour angiogenesis and growth. Conversely, simultaneous inhibition of VEGFR1 and VEGFR2 signalling results in impaired mobilization and recruitment of VEGFR1+ haematopoietic cells and VEGFR2+ CEPs to the tumour vasculature, and is highly effective in retarding the growth of certain tumours.
Characterization and quantification of VEGFR2+CEPs and VEGFR1+ haematopoietic cells in the peripheral blood, and plasma levels of VEGF, sKitL, MMP-9 and placental growth factor might lead to their use as surrogate markers for assessing the response to therapy or progression of certain malignancies. Moreover, factors that are involved in the mobilization and incorporation of CEPs and pro-angiogenic haematopoietic cells provide new targets to block tumour angiogenesis and growth.
Tumours recruit neighbouring blood vessels and vascular endothelial cells to support their own blood supply. Recent evidence has indicated, however, that tumours are also capable of mobilizing bone-marrow-derived endothelial precursor cells, inducing them to migrate to the tumour and become incorporated into the developing vasculature. Tumour-derived angiogenic factors promote the recruitment of these cells, which include circulating endothelial progenitor cells and haematopoietic stem and progenitor cells. As clinical trials with anti-angiogenic agents have been confronted with therapeutic hurdles, inhibiting the recruitment of these vascular precursors might provide a novel approach to blocking tumour angiogenesis.
Subscribe to Journal
Get full journal access for 1 year
only $21.58 per issue
All prices are NET prices.
VAT will be added later in the checkout.
Rent or Buy article
Get time limited or full article access on ReadCube.
All prices are NET prices.
Hanahan, D. & Folkman J. Patterns and emerging mechanisms of the angiogenic switch during tumorigenesis. Cell 86, 353–364 (1996).
Folkman, J., Watson, K., Ingber, D. & Hanahan, D. Induction of angiogenesis during the transition from hyperplasia to neoplasia. Nature 339, 58–61 (1989).
Tlsty, T. D. Stromal cells can contribute oncogenic signals. Semin. Cancer Biol. 11, 97–104 (2001).
Carmeliet, P. & Jain, R. K. Angiogenesis in cancer and other diseases. Nature 407, 249–257 (2000).
Yancopoulos, G. D. et al. Vascular-specific growth factors and blood vessel formation. Nature 407, 242–248 (2000).
Folkman, J. Angiogenesis in cancer, vascular, rheumatoid and other disease. Nature Med. 1, 27–31 (1995).
Lyden, D. et al. Impaired recruitment of bone-marrow-derived endothelial and haematopoietic precursor cells blocks tumor angiogenesis and growth. Nature Med. 7, 1194–1201 (2001).Demonstrates the significance of mobilization and incorporation of circulating endothelial precursor and haematopoietic cells in supporting tumour angiogenesis. Transplantation and engraftment of wild-type bone marrow into tumour-resistant Id -mutant mice results in the restoration of tumour angiogenesis and growth.
Reyes, M. et al. Origin of endothelial progenitors in human postnatal bone marrow. J. Clin. Invest. 109, 337–346 (2002).Demonstration that human endothelial cells derived from CD133+ multipotential adult progenitor (MAPC) cells injected into immunocompromised mice have the potential to contribute to tumour angiogenesis of xenotransplanted, as well as spontaneous, tumours.
Moore, M. A. Putting the neo into neoangiogenesis. J. Clin. Invest. 109, 313–315 (2002).
Asahara, T. et al. Bone marrow origin of endothelial progenitor cells responsible for postnatal vasculogenesis in physiological and pathological neovascularization. Circ. Res. 85, 221–228 (1999).
Gehling, U. M. et al. In vitro differentiation of endothelial cells from AC133-positive progenitor cells. Blood 95, 3106–3112 (2000).
Marchetti, S. et al. Endothelial cells genetically selected from differentiating mouse embryonic stem cells incorporate at sites of neovascularization in vivo. J. Cell Sci. 115, 2075–2085 (2002).
Davidoff, A. M. Bone marrow-derived cells contribute to tumor neovasculature and, when modified to express an angiogenesis inhibitor, can restrict tumor growth in mice. Clin. Cancer Res. 7, 2870–2879 (2001).
Ito, H. et al. Endothelial progenitor cells as putative targets for angiostatin. Cancer Res. 59, 5875–5877 (1999).
Arafat, W. O. et al. Genetically modified CD34+ cells exert a cytotoxic bystander effect on human endothelial and cancer cells. Clin. Cancer Res. 6, 4442–4448 (2000).
Carmeliet, P. & Luttun, A. The emerging role of the bone marrow-derived stem cells in (therapeutic) angiogenesis. Thromb. Haemost. 86, 289–297 (2001).
Dvorak, H. F., Nagy, J. A., Dvorak, J. T. & Dvorak, A. M. Identification and characterization of the blood vessels of solid tumors that are leaky to circulating macromolecules. Am. J. Pathol. 133, 95–109 (1988).
Morikawa, S. et al. Abnormalities in pericytes on blood vessels and endothelial sprouts in tumors. Am. J. Pathol. 160, 985–1000 (2002).
Bergers, G., Javaherian, K., Lo, K. M., Folkman, J. & Hanahan, D. Effects of angiogenesis inhibitors on multistage carcinogenesis in mice. Science 284, 808–812 (1999).
Holash, J. et al. Vessel cooption, regression, and growth in tumors mediated by angiopoietins and VEGF. Science 284, 1994–1998 (1999).Shows the role of vessel co-option in supporting tumour angiogenesis. The TIE2/angiopoietin signalling pathway is involved in the remodelling during co-option process.
Leung, D. W., Cachianes, G., Kuang, W. J., Goeddel, D. V. & Ferrara, N. Vascular endothelial growth factor is a secreted angiogenic mitogen. Science 246, 1306–1309 (1989).
Kim, K. J. et al. Inhibition of vascular endothelial growth factor-induced angiogenesis suppresses tumour growth in vivo. Nature 362, 841–844 (1993).
Shalaby, F. et al. Failure of blood-island formation and vasculogenesis in Flk-1-deficient mice. Nature 376, 62–66 (1995).
Terman, B. I. et al. Identification of the KDR tyrosine kinase as a receptor for vascular endothelial cell growth factor. Biochem. Biophys. Res. Commun. 187, 1579–1586 (1992).
Neufeld, G., Cohen, T., Gengrinovitch, S. & Poltorak, Z. Vascular endothelial growth factor (VEGF) and its receptors. FASEB J. 13, 9–22 (1999).
Millauer, B., Shawver, L. K., Plate, K. H., Risau, W. & Ullrich, A. Glioblastoma growth inhibited in vivo by a dominant-negative Flk-1 mutant. Nature 367, 576–579 (1994).
Pepper, M. S. & Mandriota, S. J. Regulation of vascular endothelial growth factor receptor-2 (Flk-1) expression in vascular endothelial cells. Exp. Cell Res. 241, 414–425 (1998).
Fong, G. H., Rossant, J., Gertsenstein, M. & Breitman, M. L. Role of the Flt-1 receptor tyrosine kinase in regulating the assembly of vascular endothelium. Nature 376, 66–70 (1995).
Hiratsuka, S. et al. Involvement of Flt-1 tyrosine kinase (vascular endothelial growth factor receptor-1) in pathological angiogenesis. Cancer Res. 61, 1207–1213 (2001).
Benjamin, L. E. & Keshet, E. Conditional switching of vascular endothelial growth factor (VEGF) expression in tumors: induction of endothelial cell shedding and regression of hemangioblastoma-like vessels by VEGF withdrawal. Proc. Natl Acad. Sci. USA 94, 8761–8766 (1997).
Benjamin, L. E., Golijanin, D., Itin, A., Pode, D. & Keshet, E. Selective ablation of immature blood vessels in established human tumors follows vascular endothelial growth factor withdrawal. J. Clin. Invest. 103, 159–165 (1999).
Mandriota, S. J. et al. Vascular endothelial growth factor-C-mediated lymphangiogenesis promotes tumour metastasis. EMBO J. 20, 672–682 (2001).
Skobe, M. et al. Induction of tumor lymphangiogenesis by VEGF-C promotes breast cancer metastasis. Nature Med. 7, 192–198 (2001).
Makinen, T. et al. Inhibition of lymphangiogenesis with resulting lymphedema in transgenic mice expressing soluble VEGF receptor-3. Nature Med. 7, 199–205 (2001).
Folberg, R., Hendrix, M. J. & Maniotis, A. J. Vasculogenic mimicry and tumor angiogenesis. Am. J. Pathol. 156, 361–381 (2000).
Hendrix, M. J. et al. Expression and functional significance of VE-cadherin in aggressive human melanoma cells: role in vasculogenic mimicry. Proc. Natl Acad. Sci. USA 98, 8018–8023 (2001).
Chang, Y. S. et al. Mosaic blood vessels in tumors: frequency of cancer cells in contact with flowing blood. Proc. Natl Acad. Sci. USA 97, 14608–14613 (2000).
Folkman, J. Can mosaic tumor vessels facilitate molecular diagnosis of cancer? Proc. Natl Acad. Sci. USA 98, 398–400 (2001).
Lyden, D. et al. Id1 and Id3 are required for neurogenesis, angiogenesis and vascularization of tumour xenografts. Nature 401, 670–677 (1999).Reports that Id -mutant mice fail to support the growth of xenotransplanted tumours. The mechanism for tumour resistance in Id -mutant mice is mainly due to defects in tumour angiogenesis.
Segal, M. S., Bihorac, A. & Koc, M. Circulating endothelial cells: tea leaves for renal disease. Am. J. Physiol. Renal Physiol. 283, F11–F19 (2002).
Mutunga, M. et al. Circulating endothelial cells in patients with septic shock. Am. J. Respir. Crit. Care Med. 163, 195–200 (2001).
George, F. et al. Demonstration of Rickettsia conorii-induced endothelial injury in vivo by measuring circulating endothelial cells, thrombomodulin, and von Willebrand factor in patients with Mediterranean spotted fever. Blood 82, 2109–2116 (1993).
Lefevre, P., George, F., Durand, J. M. & Sampol, J. Detection of circulating endothelial cells in thrombotic thrombocytopenic purpura. Thromb. Haemost. 69, 522 (1993).
Shi, Q. et al. Proof of fallout endothelialization of impervious Dacron grafts in the aorta and inferior vena cava of the dog. J. Vasc. Surg. 20, 546–556 (1994).
Solovey, A. et al. Circulating activated endothelial cells in sickle cell anemia. N. Engl. J. Med. 337, 1584–1590 (1997).
Asahara, T. et al. Isolation of putative progenitor endothelial cells for angiogenesis. Science 275, 964–967 (1997).Shows that bone-marrow-derived endothelial progenitors can contribute to post-natal angiogenic processes, including hind-limb ischaemia.
Shi, Q. et al. Evidence for circulating bone marrow-derived endothelial cells. Blood 92, 362–367 (1998).Shows that bone-marrow-derived cells can contribute to the endothelialization of the Dacron grafts. Most of the endothelial cells on the surface of the implanted Dacron grafts originated from the transplanted donor bone-marow-derived endothelial cells.
Lin, Y., Weisdorf, D. J., Solovey, A. & Hebbel, R. P. Origins of circulating endothelial cells and endothelial outgrowth from blood. J. Clin. Invest. 105, 71–77 (2000).Shows the potential of bone-marrow-derived circulating endothelial precursor cells to generate late outgrowth highly proliferative endothelial monolayers. By contrast, circulating endothelial cells and vascular-wall-derived endothelial cells gave rise to early outgrowth endothelial cells with limited proliferative potential.
Rafii, S. Circulating endothelial precursors: mystery, reality, and promise. J. Clin. Invest. 105, 17–19 (2000).
Takahashi, T. et al. Ischemia- and cytokine-induced mobilization of bone marrow-derived endothelial progenitor cells for neovascularization. Nature Med. 5, 434–438 (1999).
Rafii, S. et al. Characterization of haematopoietic cells arising on the textured surface of left ventricular assist devices. Ann. Thorac. Surg. 60, 1627–1632 (1995).
Gill, M. et al. Vascular trauma induces rapid but transient mobilization of VEGFR2(+)AC133(+) endothelial precursor cells. Circ. Res. 88, 167–174 (2001).
Peichev, M. et al. Expression of VEGFR-2 and AC133 by circulating human CD34(+) cells identifies a population of functional endothelial precursors. Blood 95, 952–958 (2000).This report, in conjunction with references 11 and 54 , shows that CD133 is expressed on the circulating endothelial precursor cells, and its expression diminishes after differentiation to adherent mature endothelial cells.
Quirici, N. et al. Differentiation and expansion of endothelial cells from human bone marrow CD133(+) cells. Br. J. Haematol. 115, 186–194 (2001).
Miraglia, S. et al. A novel five-transmembrane haematopoietic stem cell antigen: isolation, characterization, and molecular cloning. Blood 90, 5013–5021 (1997).
Yin, A. H. et al. AC133, a novel marker for human haematopoietic stem and progenitor cells. Blood 90, 5002–5012 (1997).
Miraglia, S., Godfrey, W. & Buck, D. A response to AC133 haematopoietic stem cell antigen: human homologue of mouse kidney prominin or distinct member of a novel protein family? Blood 91, 4390–4391 (1998).
Coffin, J. D., Harrison, J., Schwartz, S. & Heimark, R. Angioblast differentiation and morphogenesis of the vascular endothelium in the mouse embryo. Dev. Biol. 148, 51–62 (1991).
Robert, B., St John, P. L., Hyink, D. P. & Abrahamson, D. R. Evidence that embryonic kidney cells expressing flk-1 are intrinsic, vasculogenic angioblasts. Am. J. Physiol. 271, F744–F753 (1996).
Caprioli, A., Jaffredo, T., Gautier, R., Dubourg, C. & Dieterlen-Lievre, F. Blood-borne seeding by haematopoietic and endothelial precursors from the allantois. Proc. Natl Acad. Sci. USA 95, 1641–1646 (1998).
Mancuso, P. et al. Resting and activated endothelial cells are increased in the peripheral blood of cancer patients. Blood 97, 3658–3661 (2001).
Monestiroli, S. et al. Kinetics and viability of circulating endothelial cells as surrogate angiogenesis marker in an animal model of human lymphoma. Cancer Res. 61, 4341–4344 (2001).
Cameliet, P. et al. Synergism between vascular endothelial growth factor and placental growth factor contributes to angiogenesis and plasma extravasation in pathological conditions. Nature Med. 7, 575–583 (2001).
Luttun, A. et al. Revascularization of ischemic tissues by PlGF treatment, and inhibition of tumor angiogenesis, arthritis and atherosclerosis by anti-Flt1. Nature Med. 1, 1 (2002).
Polverini, P. J. & Leibovich, S. J. Induction of neovascularization in vivo and endothelial proliferation in vitro by tumor-associated macrophages. Lab. Invest. 51, 635–642 (1984).
Polverini, P. J., Cotran, P. S., Gimbrone, M. A. Jr & Unanue, E. R. Activated macrophages induce vascular proliferation. Nature 269, 804–806 (1977).
Dahlqvist, K., Umemoto, E. Y., Brokaw, J. J., Dupuis, M. & McDonald, D. M. Tissue macrophages associated with angiogenesis in chronic airway inflammation in rats. Am. J. Respir. Cell. Mol. Biol. 20, 237–247 (1999).
Ezaki, T. et al. Time course of endothelial cell proliferation and microvascular remodeling in chronic inflammation. Am. J. Pathol. 158, 2043–2055 (2001).
McDonald, D. M. Angiogenesis and remodeling of airway vasculature in chronic inflammation. Am. J. Respir. Crit. Care Med. 164, S39–S45 (2001).
Leibovich, S. J. et al. Macrophage-induced angiogenesis is mediated by tumour necrosis factor-alpha. Nature 329, 630–632 (1987).
Di Pietro, L. A. & Polverini, P. J. Angiogenic macrophages produce the angiogenic inhibitor thrombospondin 1. Am. J. Pathol. 143, 678–684 (1993).
Coussens, L. M., Tinkle, C. L., Hanahan, D. & Werb, Z. MMP-9 supplied by bone marrow-derived cells contributes to skin carcinogenesis. Cell 103, 481–490 (2000).Shows the essential role of tumour-associated macrophages in supporting tumour growth. MMP-9 that is supplied by tumour-infiltrating macrophages restores impaired tumour growth in Mmp-9-deficient mice. This indicates that MMP-9, provided by bone-marrow-derived cells, is necessary for tumour growth.
Takakura, N. et al. A role for haematopoietic stem cells in promoting angiogenesis. Cell 102, 199–209 (2000).
Donovan, M. J. et al. Brain derived neurotrophic factor is an endothelial cell survival factor required for intramyocardial vessel stabilization. Development 127, 4531–4540 (2000).
Skobe, M. et al. Concurrent induction of lymphangiogenesis, angiogenesis, and macrophage recruitment by vascular endothelial growth factor-C in melanoma. Am. J. Pathol. 159, 893–903 (2001).
Kadambi, A. et al. Vascular endothelial growth factor (VEGF)-C differentially affects tumor vascular function and leukocyte recruitment: role of VEGF-receptor 2 and host VEGF-A. Cancer Res. 61, 2404–2408 (2001).
Reya, T., Morrison, S. J., Clarke, M. F. & Weissman, I. L. Stem cells, cancer, and cancer stem cells. Nature 414, 105–111 (2001).
Krause, D. S. et al. Multi-organ, multi-lineage engraftment by a single bone marrow-derived stem cell. Cell 105, 369–377 (2001).
Blau, H. M., Brazelton, T. R. & Weimann, J. M. The evolving concept of a stem cell: entity or function? Cell 105, 829–841 (2001).
Cheng, T. et al. Haematopoietic stem cell quiescence maintained by p21Cip1/Waf1. Science 287, 1804–1808 (2000).
Vu, T. H. & Werb, Z. Matrix metalloproteinases: effectors of development and normal physiology. Genes Dev. 14, 2123–2133 (2000).
Bergers, G. et al. Matrix metalloproteinase-9 triggers the angiogenic switch during carcinogenesis. Nature Cell Biol. 2, 737–744 (2000).
Engsig, M. T. et al. Matrix metalloproteinase 9 and vascular endothelial growth factor are essential for osteoclast recruitment into developing long bones. J. Cell Biol. 151, 879–890 (2000).
Heissig, B. et al. Recruitment of stem and progenitor cells from the bone marrow niche requires Mmp-9 mediated release of Kit-ligand. Cell 109, 625–637 (2002).Shows the mechanism by which bone-marrow-derived stem and progenitor cells are recruited from the bone-marrow microenvironment to the peripheral circulation. Physiological stressors, including bone-marrow suppression or elevation of angiogenic factors, induce MMP-9, resulting in the release of soluble KIT ligand, driving the proliferation and mobilization of stem and progenitor cells.
Hattori, K. et al. Vascular endothelial growth factor and angiopoietin-1 stimulate postnatal hematopoiesis by recruitment of vasculogenic and haematopoietic stem cells. J. Exp. Med. 193, 1005–1014 (2001).
Ziegler, B. L. et al. KDR receptor: a key marker defining haematopoietic stem cells. Science 285, 1553–1558 (1999).
Sawano, A. et al. Flt-1, vascular endothelial growth factor receptor 1, is a novel cell surface marker for the lineage of monocyte-macrophages in humans. Blood 97, 785–791 (2001).
Clauss, M. et al. The vascular endothelial growth factor receptor Flt-1 mediates biological activities. Implications for a functional role of placenta growth factor in monocyte activation and chemotaxis. J. Biol. Chem. 271, 17629–17634 (1996).
Barleon, B. et al. Migration of human monocytes in response to vascular endothelial growth factor (VEGF) is mediated via the VEGF receptor flt-1. Blood 87, 3336–3343 (1996).
Cho, N. K. et al. Developmental control of blood cell migration by the Drosophila VEGF pathway. Cell 108, 865–876 (2002).
Hattori, K. et al. Placental growth factor reconstitutes hematopoiesis by recruiting VEGFR1(+) stem cells from bone-marrow microenvironment. Nature Med. 1, 1 (2002).Defines the mechanism by which angiogenic factors, including placental-derived growth factor (PlGF) and vascular endothelial growth factor (VEGF), recruit haematopoietic cells from bone marrow to the tumour vasculature. VEGFR1 is expressed on haematopoietic stem and progenitor cells and conveys signals that promote motility and MMP-9-mediated release of sKitL, thereby directing mobilization of these cells to the peripheral circulation.
Gerber, H. P. et al. VEGF regulates haematopoietic stem cell survival by an internal autocrine loop mechanism. Nature 417, 954–958 (2002).Shows the expression of VEGF receptors, including VEGFR1, on the haematopoietic stem cells, conveying signals that support proliferation and survival of these cells through a novel intrakine signalling mechanism.
Eriksson, U. & Alitalo, K. VEGF receptor 1 stimulates stem-cell recruitment and new hope for angiogenesis therapies. Nature Med. 8, 775–777 (2002).
Dias, S. et al. Inhibition of both paracrine and autocrine VEGF/VEGFR-2 signaling pathways is essential to induce long-term remission of xenotransplanted human leukemias. Proc. Natl Acad. Sci. USA 98, 10857–10862 (2001).
Dias, S. et al. Autocrine stimulation of VEGFR-2 activates human leukemic cell growth and migration. J. Clin. Invest. 106, 511–521 (2000).
Gomez-Navarro, J. et al. Genetically modified CD34+ cells as cellular vehicles for gene delivery into areas of angiogenesis in a rhesus model. Gene Ther. 7, 43–52 (2000).
Levenberg, S., Golub, J. S., Amit, M., Itskovitz-Eldor, J. & Langer, R. Endothelial cells derived from human embryonic stem cells. Proc. Natl Acad. Sci. USA 99, 4391–4396 (2002).
Vittet, D. et al. Embryonic stem cells differentiate in vitro to endothelial cells through successive maturation steps. Blood 88, 3424–3431 (1996).
Kabrun, N. et al. Flk-1 expression defines a population of early embryonic haematopoietic precursors. Development 124, 2039–2048 (1997).
Choi, K., Kennedy, M., Kazarov, A., Papadimitriou, J. C. & Keller, G. A common precursor for haematopoietic and endothelial cells. Development 125, 725–732 (1998).
Hirashima, M., Kataoka, H., Nishikawa, S., Matsuyoshi, N. & Nishikawa, S. Maturation of embryonic stem cells into endothelial cells in an in vitro model of vasculogenesis. Blood 93, 1253–1263 (1999).
Yamashita, J. et al. Flk1-positive cells derived from embryonic stem cells serve as vascular progenitors. Nature 408, 92–96 (2000).
Wijelath, E. S. et al. Novel vascular endothelial growth factor binding domains of fibronectin enhance vascular endothelial growth factor biological activity. Circ. Res. 91, 25–31 (2002).Demonstrates the capacity of fibronectin to bind to VEGF. Co-engagment of VEGFA/fibronectin with the VEGFR2/integrin complex that is expressed on endothelial cells can potentiate VEGF signalling.
This work was supported by grants from the National Heart, Lung and Blood Institute, the American Cancer Society, the Leukemia and Lymphoma Society, the Doris Duke Charitable Foundation, the Children's Brain Tumor Foundation, the National Cancer Institute and Angiogenex.
- HAEMATOPOIETIC CELLS
Are either mature, differentiated precursor cells (like monocytes or macrophages), progenitor cells or immature haematopoietic stem cells.
- HAEMATOPOIETIC STEM CELLS
Pluripotent cells that have the capacity to undergo self-renewal and stochastically differentiate into specific lineages, including the full compliment of erythroid, megakaryocytic, lymphoid and myelo-monocytic progenitors. Progenitors have limited proliferative capacity and have lost the potential to reconstitute haematopoiesis. Precursor cells, such as monocytes and macrophages, are terminally differentiated cells.
The peri-endothelial cell layer, which stabilizes the vessel-wall integrity.
- LEFT VENTRICULAR ASSIST DEVICES
(LVADs). Pulsatile, left ventricular assist devices for extended circulatory support that are implanted in patients that are awaiting cardiac transplantation. The blood-contacting surfaces of LVADs immediately colonize with haematopoietic and endothelial cells, generating a non-thrombogenic neo-intimal surface.
- EMBRYOID BODIES
Clusters of totipotent cells that are formed as a result of in vitro culture of embryonic stem cells, in the absence of supportive stroma or growth factors. Exposure of embryoid bodies to specific growth factors induces differentiation of these cells.
- LATE OUTGROWTH ENDOTHELIAL COLONIES
Incubation of bone-marrow-derived endothelial progenitors with growth factors such as VEGF, FGF2, IGF, collagen and fibronectin leads to the development of mature adherent endothelial colonies after 2 weeks. These are referred to as colony-forming units of endothelial cells (CFU-ECs). This is an unique characteristic of bone-marrow-derived endothelial progenitors, as mature vessel-wall-derived endothelial cells readily attach and proliferate, and are known as early outgrowth CFU-ECs.
About this article
Cite this article
Rafii, S., Lyden, D., Benezra, R. et al. Vascular and haematopoietic stem cells: novel targets for anti-angiogenesis therapy?. Nat Rev Cancer 2, 826–835 (2002). https://doi.org/10.1038/nrc925
The Role of Anti-angiogenesis in the Treatment Landscape of Non-small Cell Lung Cancer – New Combinational Approaches and Strategies of Neovessel Inhibition
Frontiers in Cell and Developmental Biology (2021)
Cancer Urology (2021)
Differential Angiogenic Responses of Human Endothelial Colony-Forming Cells to Different Molecular Subtypes of Breast Cancer Cells
Journal of Lipid and Atherosclerosis (2021)
DKK2 blockage-mediated immunotherapy enhances anti-angiogenic therapy of Kras mutated colorectal cancer
Biomedicine & Pharmacotherapy (2020)
World Journal of Hepatology (2020)